Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections

Please use this identifier to cite or link to this item: https://doi.org/10.1001/jamanetworkopen.2022.5750

Title:	Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
Authors:	Park, Minah Tan, Kelvin Bryan Vasoo, Shawn Dickens, Borame L Lye, David Cook, Alex R
Keywords:	Science & Technology Life Sciences & Biomedicine Medicine, General & Internal General & Internal Medicine
Issue Date:	5-Apr-2022
Publisher:	AMER MEDICAL ASSOC
Citation:	Park, Minah, Tan, Kelvin Bryan, Vasoo, Shawn, Dickens, Borame L, Lye, David, Cook, Alex R (2022-04-05). Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections. JAMA NETWORK OPEN 5 (4). ScholarBank@NUS Repository. https://doi.org/10.1001/jamanetworkopen.2022.5750
Abstract:	This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.
Source Title:	JAMA NETWORK OPEN
URI:	https://scholarbank.nus.edu.sg/handle/10635/242820
ISSN:	2574-3805
DOI:	10.1001/jamanetworkopen.2022.5750
Appears in Collections:	Elements Staff Publications

File	Description	Size	Format	Access Settings	Version
park_2022_ld_220049_1648234849.3666.pdf		420.01 kB	Adobe PDF	OPEN	Published	View/Download

Check